urea/obesity

FIELD OF THE INVENTION The presently invention relates to novel n-aryloxypropanolyl-N'-phenethyl-urea. The present invention particularly relates to the synthesis of novel N-aryloxypropanolyl-N'-phenethyl-urea derivatives of formula 3 and their use as potent appetite suppressants for treatment of

FIELD OF THE INVENTION The present invention relates to piperazine urea derivatives, their synthesis, and their use as melanocortin-4 receptor (MC-4R) agonists. More particularly, the compounds of the present invention are receptor-subtype selective partial agonists of the melanocortin-4 receptor

BACKGROUND The Silent Information Regulator (SIR) family of genes represents a highly conserved group of genes present in the genomes of organisms ranging from archaeabacteria to eukaryotes. The encoded SIR proteins are involved in diverse processes from regulation of gene silencing to DNA repair. A

FIELD OF THE INVENTION In general, the present invention relates to novel substituted bridged urea compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in sirtuin modulation and methods of for

FIELD OF THE INVENTION In general, the present invention relates to substituted bridged urea analog compounds of Formulas (I) to (V), corresponding analogs or derivatives thereof, or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of

FIELD OF THE INVENTION In general, the present invention relates to novel substituted bridged urea compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds in sirtuin modulation and methods of for

This invention relates to heteroaryl urea neuropeptide Y Y5 receptor antagonists useful in the treatment of eating disorders, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds. Neuropeptide Y (NPY) is a 36 amino acid neuropeptide that is widely

This invention relates to heteroaryl urea neuropeptide Y Y5 receptor antagonists useful in the treatment of eating disorders, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds. Neuropeptide Y (NPY) is a 36 amino acid neuropeptide that is widely

This invention relates to heteroaryl urea neuropeptide Y Y5 receptor antagonists useful in the treatment of eating disorders, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds. Neuropeptide Y (NPY) is a 36 amino acid neuropeptide that is widely

BACKGROUND OF THE INVENTION U.S. Pat. No. 4,882,432 teaches adamantyl and noradamantyl piperazine carbarnates and ureas with high 5-HT1A receptor affinities. These compounds, as well as those disclosed in U.S. Pat. No. 4,797,489 are useful for the treatment of CNS disorders. EP 661266-A1 describes

The present invention relates to compounds derived from the following chemical scaffold which is structurally defined by the formula I ##STR00002## wherein the groups R.sup.1, Y.sup.1 to Y.sup.4, V, W, and X are as defined hereinafter, including the tautomers, the stereoisomers, the mixtures

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to various 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas, and their use in the treatment of various disease states, such as

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to various 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas, and their use in the treatment of various disease states, such as

FIELD OF THE INVENTION The present invention is useful in the field of medicines. More specifically, novel pyrazole derivatives of the present invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various diseases of circulatory organs, central nervous system

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty